Citation Impact
Citing Papers
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo
2016
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Development of siRNA Payloads to Target KRAS -Mutant Cancer
2014
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Trametinib (GSK1120212) in the treatment of melanoma
2013
MEK1/2 inhibitors in the treatment of gynecologic malignancies
2014
MEK in cancer and cancer therapy
2013
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
2015 Standout
Serum test for assessment of patients with Bence Jones myeloma
2003
Melanoma: New Insights and New Therapies
2012
Lung cancer: New biological insights and recent therapeutic advances
2011
Lung cancer: current therapies and new targeted treatments
2016 Standout
Cancer-associated cachexia
2018 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Extracellular matrix structure
2015 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Targeting RAS–ERK signalling in cancer: promises and challenges
2014
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Small molecule drug screening in Drosophila identifies the 5HT2A receptor as a feeding modulation target
2013 Standout
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Prospects for MEK inhibitors for treating cancer
2014
Clonal evolution in cancer
2012 StandoutNature
Targeting the RAS pathway in melanoma
2011
MEK Inhibition in the Treatment of Advanced Melanoma
2013
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Renal clearance of quantum dots
2007 StandoutNobel
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
2012 Nature
Cancer genomics: from discovery science to personalized medicine
2011
Incidence and risk of hypertension with a novel multi‐targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta‐analysis
2013
Non-Steroidal Anti-Inflammatory Drugs Increase Cisplatin, Paclitaxel, and Doxorubicin Efficacy against Human Cervix Cancer Cells
2020
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science
2019 Standout
Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways
2018
UV Radiation and the Skin
2013 Standout
Works of Timothy Larson being referenced
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
2010
Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma
2002
Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
2009